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Abstract The future of medicine lies in early diagnosis and
individually tailored treatments, a concept that has been
designated ‘personalised medicine’ (PM), i.e. delivering the
right treatment to the right patient at the right time.
However, the value of medical imaging in PM is frequently
underestimated, as many policy makers forget the all-
important right location in the PM paradigm. Medical
imaging has always been personalised as it provides
individual assessment of the location and extent of an
abnormality, and in the future it will prove fundamental to
almost all aspects of PM. Stratification based on imaging
biomarkers can help identify individuals suited for preven-
tive intervention and can improve disease staging. In vivo
visualisation of locoregional physiological, biochemical
and biological processes using molecular imaging can
detect diseases in pre-symptomatic phases or facilitate
individualised drug delivery. Furthermore, imaging is
essential to patient-tailored therapy planning, therapy
monitoring and follow-up of disease progression, as well
as targeting non-invasive or minimally invasive treatments,
especially with the rise of theranostics. For PM to reach its
full potential, medical imaging must be an integral part.
Radiologists need to be prepared for this new paradigm as it
will mean changes in training, in research and in clinical
practice.
Keywords Individualised medicine.Diagnostic imaging.
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Introduction
‘Personalised medicine’ (PM) is increasingly becoming a
hot topic in all areas related to biomedical research and has
the potential to become the paradigm for clinical practice.
The European Commission is dedicating a conference series
to this topic [1]. The European Science Foundation (ESF)
has initiated a ‘Forward Look’ campaign that should deliver
“more precise medicine for the diagnosis, treatment and
prevention of disease” for the European citizen [2].
Regulatory bodies such as the FDA [3]a n dE M A[ 4]h a v e
been challenged to find new approaches for registration of
emerging PM technologies. National governments and
public-private collaborations are funding large research
programs and infrastructure dedicated to translation of
basic PM concepts into clinical trials. Health-policy makers
and insurance companies are in search of solutions for
future implementation of PM strategies into daily care and
reimbursement schemes.
Is PM a new concept, or is it only a new look at an old
friend? Many clinicians would argue that they have always
delivered care at the personal level and adapted their
therapeutic approach to the individual needs of every
patient. But is this really what we now regard as PM? Do
modern emerging technologies in the era of molecular
medicine allow completely new strategies? And what is the
role of medical imaging in this paradigm which mainly
focuses on different aspects of ‘disease-omics’?D o e s
medical imaging play a role in this new game?
Whatever PM is, radiologists and other imaging special-
ists have to be aware that PM is becoming and will remain
the focus of interest in medical research and health-care
policy in the coming years. Medical imaging, on the other
hand, is still recognised as one of the motors of medical
research and technology innovation, with unprecedented
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imaging wants to maintain this leading role, it will have
to define its precise position and contribution in this new
field. However, many of the policy papers, programmes and
funding schemes described above mention little or nothing
about medical imaging nor about the benefits and contri-
butions of imaging research to PM. Therefore the Research
Committee (RC) of the ESR considers it of crucial strategic
importance to define and describe how medical imaging
benefits from and contributes to the overall conceptual
framework of PM.
Definitions
According to Wikipedia, “personalized medicine is a
medical model emphasizing in general the customization
of healthcare, with all decisions and practices being
tailored to individual patients in whatever ways possi-
ble. Recently, this has mainly involved the systematic
use of genetic or other information about an individual
patient to select or optimize that patient’sp r e v e n t a t i v e
and therapeutic care” [5]. In other words, PM describes
the concept of delivering the right treatment to the right
patient at the right time. PM is facilitated by newly
developed, powerful technologies allowing detection of
“biological events at the molecular level, even before
symptoms appear. The promise of personalised medicine
is a future where disease is detected at the earliest possible
time, and treatments are tailored to an individual patient’s
genetic profile” [6].
Sequencing of the human genome in 2003 opened the
way to identify specific genes that are involved in particular
diseases and thus to define genetic variants which either
predispose a person to that disease or which regulate that
person’s sensitivity to a given treatment [2]. The concept of
using these genetic differences to personalise healthcare has
since taken over the perception of PM to such an extent that
other means of personalising healthcare are being sub-
sumed. However, except for a few monogenic diseases,
proteins and other molecules (the ‘omics’ of that specific
disease) have a more important influence on determining
disease predisposition or therapeutic response than knowl-
edge of the genetic sequence [2, 7]. Moreover, individual
genetic differences have to be considered in the context of
additional external variations—environment, diet, exercise,
social circumstances—leading to variation in disease
manifestation and drug activity [6].
The ESF expects that integration of several different
‘omics’ measurements will be needed to yield clinically
useful biomarkers which can be used in tailoring
treatment to an individual’s physiological and biochem-
ical profile [2]. Other terms used in the context of PM,
such as integrated medicine, theranostics, pharmacodiag-
nostics and diagnostic/therapeutic partnering “address the
use of detailed information about a patient’s genotype or
level of gene expression and a patient’s clinical data [or
biomarkers] to select medication, therapy or preventative
measures that are particularly suited to that patient” [8].
Thus, one of the main aspects of PM will be to identify
biomarkers able to characterise a cellular alteration
leading to subclinical or manifest disease status as well
as its specific reaction to various therapeutic attempts [9].
However, this approach again will lead to categorising or
stratifying patients into smaller subgroups related to their
risk or potential treatment profiles characterised by a
combination of genetic, biochemical and even imaging
biomarkers [10]. Such stratification can be further refined
down to the level of an individual patient, and the term
‘individualised medicine’ could be more appropriate.
Indeed, the National Library of Medicine has selected
‘individualized medicine’ as the Medical Subject Heading
(MeSH) term for PM.
There are three main areas in which PM is expected to
have a major health-management impact: in preventive
medicine, in personalised diagnosis of disease and in
therapeutic decisions targeting specific alterations. The
disease prevention focus is on identifying—in an early
pre-clinical stage—those subgroups of patients at risk of
developing symptoms and signs of abnormal morphology
and function. Such personalised prognostic stratification
strategies may rely on genetic, environmental, social and
other information. Identification of predictive biomarkers
(biomolecular or imaging) can help to monitor disease
development and preventive interventions. Personalised
diagnostics implies the identification of the specific
molecular substrate of alterations leading to disease. While
most think of disease phenotype as answering the question:
‘What is it?’, an important part of personalised character-
isation (and thus an integral part of PM) is location (‘Where
is it?’) and extent (‘What is involved?’). Furthermore, a
complete diagnosis also needs information on the physio-
logical characteristics of disease lesions (e.g. perfusion,
flow, metabolism, diffusion). Personalised treatment focus-
es on the identification of patient subgroups likely to give a
positive response to a given treatment [11], on the
identification of subgroups of patients at risk of side effects
during treatment [11], on monitoring of therapy response
[11] and on individualised drug delivery systems allowing
both real-time modulation of treatment approach and
treatment delivery at a specific location. In other words,
as Michael Berger so eloquently phrased it, “medical
treatment tailored not just to symptoms, but to the
biochemical profile of an individual’s disease state (gene
expression, proteome, dominant metabolic pathways, etc.)”
[12].
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In a critical description on the role of molecular imaging in
PM, Adrian Nunn states: “For too long, it has been
assumed that non-imagers understand the value of imaging
not only from the research side, but also from the health
care economics side. This has led to an underestimation of
the value of imaging and, for molecular imaging, perhaps
an idea that it is ‘science’ rather than high-value routine
health care” [7]. Individual assessment of the location and
extent of an abnormality is and always has been the basis
of medical imaging, whether the ‘abnormality’ is a
disease, a malformation or an injury. As such, medical
imaging intrinsically enables PM. Examples of the
unique and personalised information provided with
imaging technologies are numerous: imaging allows
localisation of disease and detection of the involvement
of adjacent or more distant tissues and vital structures;
imaging helps to plan and guide surgical or minimally
invasive individualised therapies; and imaging enables
assessment of the physiological environment and con-
ditions of disease as well as prediction of the efficacy or
possible side effects of treatment (assessing perfusion of
lesions or diffusion in tissue as well as the vulnerability
of adjacent organs).
In its ‘Science policy briefing 28: medical imaging for
improved patient care’ [9], the ESF states that:
Traditionally, medical imaging was a tool for non-
invasive mapping of anatomy and for detection and
localization of a disease process. However, consecu-
tive to a paradigm shift, it has been demonstrated that
a wide variety of new medical imaging techniques
and methods produce important biological informa-
tion about physiology, organ function, biochemistry,
metabolism, molecular biology and functional
genomics. These new methods combine the ability
to measure and quantify biological processes with the
ability to localise the measured entities into a high-
quality anatomical image. Further, advanced imaging
techniques are now used for treatment instead of
surgery: e.g. coronary angioplasty, treatment of aortic
aneurysm and coiling of bleeding cerebral aneurysms.
Exciting new advances in medical imaging are based
on research in the areas of functional and molecular
imaging and in the area of development of imaging
biomarkers for improved prevention, diagnosis and
treatment of disease.
PM will mean changes for radiology. According to
Jim Thrall, “Imaging will play an increasingly important
role in the assessment of therapeutic response, especial-
ly in cancer” [13]a st h i si sa na r e ai nw h i c hv a r i a b i l i t y
among patients opens the door for individually tailored
medications. According to a new market research report,
interests from the imaging industry will drive PM in
general and molecular medicine in particular [14]. Others
recognise the threat which in vitro testing poses and
maintain that we must rely on the unique ability of
imaging to provide regional information, ideally including
information on function, which cannot be replaced by ex
vivo tests [7].
In her Presidential Address at the 2010 RSNA Annual
Meeting, Hedvig Hricak, Chair of the Department of
Radiology at Memorial Sloan-Kettering Cancer Center in
New York, stated that medical imaging has become “a
‘guiding hand’ of personalized medicine for cancer care”
[15]. Prof. Hricak names three categories in which imaging
impacts PM: treatment decision-making, treatment planning
and treatment follow-up. “Imaging provides essential road-
maps for treatment planning” [15]. Hricak expects advances
in techniques such as quantitative imaging and volumetric
measurements to “change the landscape of clinical trials”
[15]. Areas of opportunity for imaging in the era of PM
include the following:
– Identification of predictive imaging biomarkers allow-
ing both stratification of patient subgroups at risk of
developing disease and monitoring of preventive
measures
– Visualisation of cellular and molecular processes for
early diagnosis of disease with the emerging discipline
of molecular imaging
– Theranostics combining targeted imaging and targeted
therapy enabling the identification of heterogeneous
and localised response to therapy
– Treatment monitoring allowing early identification of
treatment responders and non-responders
– Identification of localised pathophysiology (perfusion,
diffusion, metabolism) of diseased tissue
– Individualised, image-guided drug delivery systems
However, implementing imaging-based PM strategies in
clinical care is hampered by inadequate regulatory proce-
dures. Both in Europe and in the U.S., new approval
processes for PM approaches are needed [10]. This is a
complex proposition given the mass of individual data and
treatment options that arise from a PM approach, especially
when imaging is involved. Adrian Nunn discusses both
short- and long-term solutions: “In the short term, … ways
[can] be explored to ease development and regulation of
molecular imaging agents to foster development ‘in spite
of’ the current framework. … The long-term approach
[could be] to assess the feasibility and desirability of an
alternative regulatory mechanism for molecular imaging
agents” [7]. The FDA and EMEA must acknowledge the
crucial role of medical imaging in PM in order to achieve
durable policies for this field.
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Biomedical imaging allows non-invasive or minimally
invasive assessment of in vivo structural and functional
changes that may reflect specific pathology. Recent devel-
opments in image data acquisition and analysis enable use
of these techniques on a large scale. This makes it possible
to investigate specific pathophysiological substrates of
disease in a pre-symptomatic phase and at the population
level. Population imaging is the large-scale application and
analysis of medical images in controlled population
cohorts. Population imaging focuses on finding imaging
biomarkers that allow prediction and early diagnosis of
diseases and preventive therapy.
Many common diseases are complex conditions caused
by a large number of small, often additive effects arising
from genetic predisposition, lifestyle and the environment.
The development of new prevention strategies, leading to
the promotion of health, requires access to and use of
searchable repositories of biomedical data from population-
based, prospective health surveys. These repositories
include imaging data together with associated information
about the individual subject. They have become indispens-
able for elucidating molecular processes and causal path-
ways, be they genetic or environmental, and for translating
biomedical research into real improvements in healthcare
(www.populationimaging.eu). Population imaging endeav-
ors to find imaging biomarkers that can predict later
development of disease, either on their own or by
supplementing established risk factors. Clinical phenotyp-
ing and correlation with genome-wide analysis aid the
search for genetic mutations predisposing one to a specific
disease by “aggregating subjects into groups with higher
probabilities of having common genotypes” [13]. Some
even believe that successful identification of prognostic
biomarkers will reduce the number of surgeries [2]. Several
projects performed in healthy populations have already
shown that imaging has benefits for the determination of
disease predictors and can enable the stratification of a
healthy population into different risk categories. Imaging
may become the key to identifying people that could
benefit from preventive intervention (Fig. 1).
Prof. Dr. Olga Golubnitschaja—Secretary-General of the
European Association for Predictive, Preventive and Per-
sonalised Medicine (EPMA)—summarised the situation
well in her landmark book Predictive Diagnostics and
Personalized Treatment: Dream or Reality [16]:
Essential components of [predictive, preventive and
personalized medicine] include well-organized popu-
lation screening protocols utilizing novel diagnostic
biomarkers of disease states, targeted prevention of
common human pathologies, optimal treatment plan-
ning and personalized medicine thereby resulting in
substantial improvement of the quality of life. This
approach also offers the advantage of delivering care
at potentially reduced costs to the population at large
thereby addressing social and ethical issues related to
access to and affordability of health care.
The flip side of the preventive medicine coin involves
incidental findings and overdiagnosis. In a cohort of
subjects undergoing a CT angiography of the abdominal
aorta and the lower extremities, 15% of patients had
incidental findings of potential clinical relevance [17], and
similar rates have been reported in healthy subjects
undergoing cranial MRI for research purposes [18]. When
an asymptomatic disease is diagnosed (either by screening
or as an incidental finding), we have the potential for
overdiagnosis. Overdiagnosis is the diagnosis of irrelevant
diseases, diseases which are so stable or indolent that they
would not have become clinically relevant during the
subject’s life. Overdiagnosis leads to unneeded treatment
with potentially harmful side effects and thus causes both
economic and emotional burden. The magnitude of over-
diagnosis has been recently estimated to be as much as 25%
of mammographically detected breast cancers, 50% of chest
x-ray and/or sputum-detected lung cancers, and 60% of
prostate-specific antigen-detected prostate cancers [19]. The
challenge for PM is to recognise when the burdens of
treatment outweigh the benefits for a given patient, taking
into account the individual characteristics of the subject,
including his or her personal values and preferences.
Medical imaging for personalised diagnosis
In classical diagnostic imaging, information is primarily
derived from differences in how various tissues intrinsically
respond to the imaging modality or the compartmentalisa-
tion of simple contrast agents, thus showing morphology.
While classical macroscopic imaging provides some of the
most important ‘individualised’ information on many
diseases—namely their localisation and extent—its value
for determining the specific aetiology is sometimes limited.
Final diagnosis within an acceptable degree of uncertainty
is usually possible based on a combination of clinical,
biochemical and imaging information (Fig. 2). However,
establishing the cellular, molecular, or genetic pathways
leading to disease requires microscopic, metabolic and/or
functional information. Such information can be obtained
by ex vivo analysis of tissue, and image-guided tissue
sampling provides the means to target and investigate
specific areas of the lesions.
Molecular imaging is a new, in vivo approach which is
likely to replace several aspects of ex vivo tissue analysis
and which will be key in realising PM. Molecular imaging
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biological processes at the cellular and molecular level in
living organisms and determine changes in local biochem-
istry [12]. Multiple methods and biomarkers have now been
described for imaging the temporal and spatial biodistribu-
tion of a molecular probe as well as related biological
processes such as cell proliferation, apoptosis, angiogene-
sis, hypoxia and gene activation and expression [20]. These
molecular imaging techniques can lead to enhanced,
individualised clinical management of diseased patients at
an early stage. For instance, ‘reporter genes’ which are part
of a gene therapy can be used to determine if transfection
was successful and to monitor gene activity and distribution
in the individual patient [13]. Molecular imaging is
intrinsically different from the large, in vitro genomic or
proteomic arrays currently popular. Such arrays survey a
large number of genes or proteins, while molecular imaging
concentrates on just one or two proteins. However, the
“apparent reduction in utility, because of the smaller
number of analytes, is more than compensated by the
regional and dynamic information [molecular imaging]
provides” [7].
A major area where diagnostic imaging techniques have
been used extensively is disease staging. Staging, or in
other words the description of disease extent (and implicitly
severity), has an immediate and important impact on choice
of therapeutic options and on personalised prognostic
stratification. Methods commonly used for staging are
those that combine fast whole-body coverage with high
sensitivity for disease detection. The whole-body approach
and sensitivity of diffusion-weighted MRI and PET-CT are
useful in disease staging, allowing assessment of the
disease status of a patient and selection of the most
appropriate treatment approach for that patient from a
single examination [21, 22]. Staging and stage migration
using different cross-sectional imaging techniques such as
CT, MRI or PET help avoid futile operations, resulting in
improved personalised treatment and reduced patient
morbidity. Similarly, precise delineation of primary and
metastatic lesions helps to optimise target volume definition
Fig. 2a, b Novel imaging techniques contribute to personalised
diagnosis. Delayed gadolinium-enhanced magnetic resonance imaging
of cartilage (dGEMRIC) in a patient with complaints of early knee
osteoarthritis (a) and a patient without knee complaints (b). With
dGEMRIC it is possible to quantitatively assess cartilage quality
before the onset of morphological changes, by measuring its
glycosaminoglycan content. In patient a, decreased dGEMRIC index
is shown particularly in the weight-bearing cartilage of the femoral
condyle and tibial plateau compared to patient b. This indicates
reduced glycosaminoglycan content, and hence reduced cartilage
quality, in the early osteoarthritic knee. Novel quantitative radiological
techniques such as dGEMRIC may aid in personalised therapeutic
decision-making in early stage osteoarthritis because patients who are
likely to benefit from therapeutic interventions can be identified more
accurately
Fig. 1 Imaging to identify beneficiaries of preventive medicine.
Elevated calcium score with associated chronic total occlusion of the
left anterior descending coronary artery (LAD) in a 79-year-old male.
a Axial unenhanced image shows calcifications in the LAD, in the
circumflex (CX) coronary artery and in the right coronary artery
(RCA). b The calcifications in the three coronary arteries are colour
coded by the automated calcium detection algorithm. The total
Agatston calcium score in this patient was 637, suggesting increased
risk for a coronary event. c CT coronary angiography demonstrates an
obstructive coronary stenosis due a mixed plaque in the proximal
LAD (C1) and a chronic total occlusion in the mid LAD (C2)
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use of brain tracts can aid in optimal surgical planning for
tumours of the brain [23]. Clearly, novel macroscopic and
molecular imaging techniques will form the cornerstone of
personalised diagnosis in the near future.
Medical imaging for personalised therapy
Medical imaging contributes to therapeutic PM in several
key areas. The role of medical imaging in personal, patient-
tailored therapy planning, therapy monitoring and follow-
up of disease progression is obvious to most medical
professionals, but medical imaging also contributes to
personalised therapy via image guidance of minimally
invasive interventions as well as targeting of non-invasive
focused ultrasound or radiation treatments.
In many diseases ‘one size fits all’ no longer applies.
The application of medical imaging is changing treatment
management to a tailored approach, with both health and
economic benefits. Treatment monitoring helps avoid both
unnecessary drug toxicities and ineffective treatments, with
resultant reduction in healthcare costs [21]. Molecular
imaging not only allows detection of disease in very early
or even pre-clinical stages but also helps to determine
subsequent personalised therapies. It may be also used for
prognostic classification and for the choice of personalised
follow-up strategies [21]. Furthermore, “molecular imaging
may provide unique means for the selection of patients who
may benefit from targeted therapies, as well as [allowing]
monitoring of early responses to treatment and [enabling]
subsequent restaging” [20]. Image-guidance of biopsy
sampling (by US or CT) helps to obtain relevant material
for the in vitro mapping of the genetic expression and
biology of the individual disease, while metabolic imaging
using PET-CT is useful for selecting cancer patients who
are likely to respond to specific radiopeptide treatments and
this examination can also be used as a baseline for response
monitoring [22]. Therapeutic applications of imaging
within PM can be categorised into four areas: drug
discovery, theranostics, image-guided interventions and
drug delivery, and therapy monitoring.
Drug discovery
Imaging is establishing itself as a vital part of pharmaco-
logical research, where it can be used to identify and
evaluate novel target moieties. Indeed, in its Critical Path
Initiative, the U.S. Food and Drug Administration (FDA)
has recognised the new role of medical imaging in drug
development and regulatory approval [24]. Although the
Initiative emphasises the role of imaging in assessment of
biomarkers, medical imaging also has other applications in
drug discovery: “a molecular imaging probe can be used to
determine target occupancy before and after administration
of a new drug candidate, which helps to assess binding
affinity and to determine correct dosages” [13].
Very important is the rise of (imaging) biomarkers as
surrogate endpoints for clinical trials. Biomarkers that
indicate response to therapy may be the same as those used
for diagnosis or characterisation, but do not have to be.
Given that validated surrogate endpoints allow dramatic
shortening of clinical trials, with associated savings and a
faster availability of new treatments, this is an area in which
both the pharmaceutical industry and the healthcare
authorities are pushing for biomarker use. Molecular
imaging and radiopharmaceuticals are particularly impor-
tant within this context as they allow in vivo visualisation
of the effect of the treatment. Indeed, Adrian Nunn feels that
the “interest in imaging agents generated by the Critical Path
Initiative probably means that all new imaging agents—
molecular or morphologic, existing technologies or new
technologies—will be seen in a new light” [7].
Theranostics
According to Wikipedia, theranostics is “the term used to
describe the proposed process of diagnostic therapy for
individual patients—to test them for possible reaction to
taking a new medication and to tailor a treatment for them
based on the test results” [25]. Theranostics are inextricably
linked to PM as they are individualised products providing
both diagnosis and treatment. The most common example
of a theranostic is targeted radionuclide therapy. Targeted
radionuclide therapy combines “the favorable targeting
properties of peptides and antibodies with the effectiveness
of radiation-induced cell death. A major advantage … is the
possibility to determine the selective accumulation in the
targeted tissue by molecular imaging studies … using
structurally identical diagnostic compounds” [20]. Depend-
ing on the exact radionuclide used, theranostics provide
both a unique signature for imaging the biodistribution of
the target moiety (diagnosis and monitoring) and micro-
environmental radiotherapy (treatment) and permit one to
predict the biodistribution of radiation dose, stage the
tumour and individually monitor the efficacy of treatment
with the same basic compound that is being used to target
and treat the disease [20]. “This novel class of pharma-
ceuticals offers the potential to develop patient-specific
therapies based on the new ‘image and treat’ approach”
[20].
Alternatively, different biomarkers can be combined to
characterise the diseased tissue [21]. These “visible”
pharmaceuticals have enormous potential in PM.
The evolving era of nanotechnology will further boost
the development and use of theranostics. New materials and
techniques are facilitating the production of various nano-
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carrier. Currently various types of nanoparticles are being
investigated as versatile tools for theranostics purposes [26,
27]. A major advantage of nanoparticles for theranostics
would be the high payload of both therapeutic agent and
imaging probe that can be delivered to the target tissue.
Specific examples of theranostic agents currently under
investigation include liposomal vesicle formulations con-
taining cytostatic drugs and MR contrast agents [28, 29],
carbon nanotubes as multifunctional carriers for radio-
isotopes for treatment and imaging [30], and dendriworms
for efficient delivery of siRNA (small interfering RNA)
visualised by optical imaging or MRI [31]. An additional
new approach in theranostic strategies is ‘cellular thera-
nostics’. In this approach, cells would be used for
diagnostic as well as therapeutic purposes [32, 33].
Image-guided interventions and drug delivery
Image-guided interventions provide the means to deliver
therapies locally at the disease site, whether the therapies
are based on chemical compounds (including drugs and
radiotherapeutics), genes, devices (including stents), cells,
sound waves (HIFU) or temperature fluctuations (hyper-
and hypothermia). Most current interventional image-
guided procedures are individually tailored to the local
anatomic and functional circumstances as well as the
personal needs of the patient. In this way, image-guided
interventions are in themselves an important and integral
part of PM.
Medical imaging also plays an important role in
individualised drug delivery, by providing information
about the locoregional physiological conditions (‘regional
proteomics’ [7]) important for drug targeting [10], by
triggering nanotechnological carriers to release active drug
[10] or by monitoring differentiation of stem cell–based
therapeutics [9]. Although the past 30 years of drug
delivery research have focused on targeting carriers such
as liposomes, polymeric nanoparticles and micelles to the
disease site, new developments promote the selective
release of bioactive compound after application of a trigger
[10]. The trigger mechanism can be applied locally and at
specific times, depending on the individual patient’s needs,
and can be selectively applied with interventional techni-
ques such as high intensity focused ultrasound (HIFU)
under the guidance of MRI [10]. “[HIFU] is the only
clinically viable technology that can be used to achieve a
local temperature increase deep inside the human body in a
non-invasive way. … MRI can be used to provide
continuous temperature mapping during HIFU for spatial
and temporal control of the heating procedure and
prediction of the final lesion based on the received thermal
dose” [34]. Other molecular imaging–based approaches for
PM are also invading the field of image-guided interven-
tions, including approaches involving gene expression,
drug activation and drug delivery. These types of techni-
ques can be further combined with specially designed
contrast agents or drug delivery systems to achieve even
more personalised approaches.
Therapy monitoring
Therapy monitoring is an area which PM is expected to
dominate within a few years. Current monitoring is based
mainly on anatomical imaging—frequently still assessed on
2D images (e.g. according to the RECIST criteria). This
field is a paradigmatic example of the gap between current
practice and advances in technological imaging. However,
the new RECIST 1.1 criteria [35] have expanded to include
lymph node evaluation and the use of PET.
New approaches using molecular imaging will document
changes in local biochemistry or physiology as well as
anatomy, which should provide even earlier differentiation
between responders and non-responders. The simplest
version of this is
18F-fluorodeoxyglucose (
18FDG) imaging
(Fig. 3), which assesses the glucose uptake and thus the
metabolic activity level of various cancers [7], but more
specific probes can and are being developed for individual
types of cancer [36]. “One can foresee the further
expansion of PET imaging–based personalised management
of cancer, which, based on the strong evidence generated
through a number of clinical studies and by its ability to
monitor disease activity at the individual level, is likely to
be increasingly integrated into the standard evidence-based
clinical practice of oncology” [22].
There is one problem with monitoring approaches based
on a single marker, a problem which has plagued physicians
in oncology and related fields for decades: the heteroge-
neity of tumours. While tumour heterogeneity also explains
individual variations in treatment response, a monitoring
approach based only on a single marker is sensitive to
variations in expression of that marker. “This defines the
weakness of serum analyses, which provide an average
signal of output from all lesions, or of a biopsy program to
characterize a tumor—if all can be different, then all must
be characterized” [7]. Signal localisation and regional
differences are the strength of imaging. Thus, “imaging
biomarkers may be used as a surrogate outcome measure
for the biological behaviour of different diseases” [9].
However, molecular imaging approaches based on a
single probe may be insufficient, especially as alternative
pathways may replace the function of the targeted pathway
[7, 8], resulting in a false negative test outcome. This
seeming weakness, however, can actually be a strength—by
combining imaging markers from different pathways, it
may be possible to assess the type of physiological escape
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tumour presence [8], enabling individual treatment to be
fitted in real time to the type of response, which is of course
PM in its most basic sense. However, a real concern when
using expensive molecular imaging agents is cost-
effectiveness—“to demonstrate that the increased cost of
the imaging provides a commensurate increase in value”
[7].
Conclusions
While Jim Thrall’s 2004 statement that “each individual is
now an ‘n’ of one” [13] was certainly premature, the
essence is correct: PM will probably take over medical care
in the near future. However, many reports on PM fail to
recognise the important role that medical imaging must
play in a PM approach.
In the not all too distant future, each patient will expect
completely individualised prediction, diagnosis and treat-
ment. Radiologists need to be prepared for this new
paradigm as it will mean changes in training (PM should
be included in post-graduate education), in research (e.g.
with a stronger role of radiologists in pharmacological
research) and in clinical practice (taking into account the
whole profile of the patient, including genetics, risk factors
and personal values and preferences). In order to adapt
medical care to the individual situation, knowledge is
needed, not only about the biochemical and physiological
characteristics of the individual’s disease, but also about
location, extent and inter- and intra-lesion heterogeneity.
To gain this knowledge, biomarkers of different types
will need to be combined. Genomics- and proteomics-
based biomarkers are imperative, as are imaging-based
biomarkers.
The ‘three R’s’ of PM are right treatment, right time,
right location. Medical imaging is essential for excellent
PM as it is the only patient-friendly means to obtain
information on location, especially with regard to hetero-
geneous expression within an individual patient. However,
medical imaging can also contribute important information
regarding expression patterns, perfusion, metabolic activity
etc., which can be pivotal in deciding what the best
treatment is, and when is the best time to give it.
Fig. 3
18FDG imaging to monitor cancer treatment. Computed
tomography (CT, left),
18FDG positron emission tomography (PET,
right) and PET/CT fusion (middle) images in a patient with Hodgkin’s
lymphoma, evaluated after eight courses of chemotherapy. Intense
hypermetabolism on FDG-PET corresponds with localisation on CT in
a small right supraclavicular lymph node, clearly indicating recurrent
lymphoma. (Figure courtesy of Dr. Roelf Valkema, Department of
Nuclear Medicine, Erasmus MC)
628 Insights Imaging (2011) 2:621–630Furthermore, medical imaging plays a critical role in all
aspects of PM: prediction, diagnosis and especially treat-
ment. For PM to reach its highest potential, medical
imaging must be an integral part.
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